Novel Assay Measures Interleukin-6 in Whole Blood Samples
By LabMedica International staff writers Posted on 05 Oct 2021 |
Image: The Pylon 3D Fully Automated Immunoassay System (Photo courtesy of ET Healthcare)
Interleukin 6 (IL-6) is a pleiotropic cytokine produced by various stromal cells and immune system cells, involved in inflammation and infection responses, regeneration process, metabolism regulation, bone homeostasis, and neural functions.
Interleukin 6 assays are useful in early detection of infections and risk stratification of critically ill patients, so an assay with a short turnaround-time and near-patient use is preferred. It is indicated in many diseases such as infection, injury, trauma, stress, neoplasia, post-surgery complications, and chronic inflammatory diseases.
Clinical Laboratorians at the Children’s Hospital of Fudan University (Shanghai, China) included in a study pediatric patients, admitted to the Emergency Department (ED) between April and September 2020 with suspected infection. Blood samples and respiratory tract samples were collected for routine clinical laboratory tests, that is, hematology tests, CRP, PCT, viral antigen, or antibody tests and microbiology culture tests.
The study evaluated the performance of the Pylon IL-6 assay (ET Healthcare, Shanghai, China) based on a cyclic enhanced fluorescent immunoassay performed on a fully automated, benchtop Pylon 3D immuno-analyzer. A total of 100 remnant serum samples from outpatients and ED patients were measured by the Pylon assay and the Elecsys IL-6 assay on a Cobas e 602 (Roche Diagnostics, Rotkreuz, Switzerland). The team carried out imprecision, linearity and comparison studies using serum and plasma samples according to CLSI EP guidelines. The stability of whole blood (WB) samples during storage was assessed.
The investigators reported that the results of serum samples measured by Pylon assays correlated to those measured by Roche assays, as well as to those of matched whole blood samples measured by Pylon assays. IL-6 in whole blood was found stable for ~8 hours at room temperature. Pylon IL-6 results of whole blood samples from 179 pediatric patients with suspected infection showed an AUC of 0.842 in diagnosis of bacterial infection. The within-run CVs and total CVs of Pylon IL-6 assay were determined as 1.8% and 3.0% at 159.3 pg/mL and 3.5% and 4.7% at 8009.9 pg/mL, respectively. The method showed linearity between 1.5 and 42,854 pg/mL. The turnaround time of Pylon IL-6 assay was only an hour when using whole blood samples.
The authors concluded that the new Pylon IL-6 assay demonstrated comparable performance to those assays performed on clinical laboratory instruments. Further, the feature of WB sampling offers advantages in ED or other near-patient settings where turnaround time (TAT) is critical. The study was published on September 20, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Children’s Hospital of Fudan University
ET Healthcare
Roche Diagnostics
Interleukin 6 assays are useful in early detection of infections and risk stratification of critically ill patients, so an assay with a short turnaround-time and near-patient use is preferred. It is indicated in many diseases such as infection, injury, trauma, stress, neoplasia, post-surgery complications, and chronic inflammatory diseases.
Clinical Laboratorians at the Children’s Hospital of Fudan University (Shanghai, China) included in a study pediatric patients, admitted to the Emergency Department (ED) between April and September 2020 with suspected infection. Blood samples and respiratory tract samples were collected for routine clinical laboratory tests, that is, hematology tests, CRP, PCT, viral antigen, or antibody tests and microbiology culture tests.
The study evaluated the performance of the Pylon IL-6 assay (ET Healthcare, Shanghai, China) based on a cyclic enhanced fluorescent immunoassay performed on a fully automated, benchtop Pylon 3D immuno-analyzer. A total of 100 remnant serum samples from outpatients and ED patients were measured by the Pylon assay and the Elecsys IL-6 assay on a Cobas e 602 (Roche Diagnostics, Rotkreuz, Switzerland). The team carried out imprecision, linearity and comparison studies using serum and plasma samples according to CLSI EP guidelines. The stability of whole blood (WB) samples during storage was assessed.
The investigators reported that the results of serum samples measured by Pylon assays correlated to those measured by Roche assays, as well as to those of matched whole blood samples measured by Pylon assays. IL-6 in whole blood was found stable for ~8 hours at room temperature. Pylon IL-6 results of whole blood samples from 179 pediatric patients with suspected infection showed an AUC of 0.842 in diagnosis of bacterial infection. The within-run CVs and total CVs of Pylon IL-6 assay were determined as 1.8% and 3.0% at 159.3 pg/mL and 3.5% and 4.7% at 8009.9 pg/mL, respectively. The method showed linearity between 1.5 and 42,854 pg/mL. The turnaround time of Pylon IL-6 assay was only an hour when using whole blood samples.
The authors concluded that the new Pylon IL-6 assay demonstrated comparable performance to those assays performed on clinical laboratory instruments. Further, the feature of WB sampling offers advantages in ED or other near-patient settings where turnaround time (TAT) is critical. The study was published on September 20, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Children’s Hospital of Fudan University
ET Healthcare
Roche Diagnostics
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms